Boston Common Asset Management’s Quest Diagnostics DGX Stock Holding History

Boston Common Asset Management’s Portfolio DGX Stock Details DGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$20.3M	Buy	95,696 +5,370	+6%	+$1.05M	1.2%	20
2026 Q1	$17.7M	Buy	90,326 +13,037	+17%	+$2.53M	1.14%	21
2025 Q4	$13.4M	Sell	77,289 -16,756	-18%	-$3.05M	0.81%	36
2025 Q3	$17.9M	Buy	94,045 +19,795	+27%	+$3.51M	0.5%	65
2025 Q2	$13.3M	Buy	+74,250	New	+$12.9M	0.37%	98
2023 Q4	–	Sell	-1,995	Closed	-$243K	–	308
2023 Q3	$243K	Sell	1,995 -132,722	-99%	-$17.7M	0.01%	289
2023 Q2	$18.9M	Sell	134,717 -5,959	-4%	-$821K	0.4%	96
2023 Q1	$19.9M	Buy	140,676 +24,584	+21%	+$3.52M	0.41%	87
2022 Q4	$18.2M	Buy	+116,092	New	+$16.7M	0.87%	42
2014 Q3	–	Sell	-250	Closed	-$15K	–	282
2014 Q2	$15K	Hold	250	–	–	﹤0.01%	322
2014 Q1	$14K	Buy	+250	New	+$13.4K	﹤0.01%	361
2013 Q4	–	Sell	-1,120	Closed	-$69K	–	316
2013 Q3	$69K	Hold	1,120	–	–	﹤0.01%	316
2013 Q2	$68K	Buy	+1,120	New	+$66.7K	﹤0.01%	306

Other funds holding DGX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

EIG

EdgePoint Investment Group Toronto, Ontario, Canada $13.2B AUM 32.43% 1-Year Est. Return

Boston Common Asset Management's DGX Position: Q2 2026 in Review

Boston Common Asset Management increased its Quest Diagnostics (DGX) stake by 5.9% in Q2 2026, buying an estimated $1.05M and bringing the position to 95,696 shares worth $20.3M. The position accounts for 1.2% of the portfolio, ranked #20.

Boston Common Asset Management first reported a position in DGX in Q2 2013 and has held it in 13 quarters since. 1,100 funds tracked by Wall St. Rank hold DGX as of Q2 2026.

Boston Common Asset Management held 95,696 shares of Quest Diagnostics worth $20.3M as of Q2 2026.
Boston Common Asset Management bought 5,370 Quest Diagnostics shares in Q2 2026, an estimated $1.05M.
Quest Diagnostics made up 1.2% of Boston Common Asset Management's portfolio in Q2 2026, its #20 holding.
Boston Common Asset Management first reported a position in Quest Diagnostics in Q2 2013 and has held it in 13 quarters since.
1,100 funds tracked by Wall St. Rank held Quest Diagnostics as of Q2 2026.

Based on Boston Common Asset Management's 13F filing for Q2 2026, filed 21 Jul 2026.